Selepeg 400 µg contains Selexipag, a selective IP prostacyclin receptor agonist used to treat pulmonary arterial hypertension (PAH). It is prescribed to slow disease progression, improve exercise capacity, and reduce the risk of hospitalization in patients with Group 1 PAH

Mechanism of Action
Selexipag mimics the natural substance prostacyclin, activating the IP receptor in the blood vessels of the lungs. This causes the vessels to relax and widen, improving blood flow and reducing pressure in the pulmonary arteries. It also inhibits smooth muscle cell proliferation, helping to prevent further vessel narrowing

Uses
Selepeg is prescribed for:

• Pulmonary arterial hypertension (PAH) in adults (WHO Group I), particularly those in functional Class II or III

• As part of combination therapy in PAH to delay disease progression and reduce hospitalizations

  Adverse Effects
  Common side effects, usually mild and transient, include:

  • Headache, flushing (feeling of warmth in face, neck, or body)

  • Jaw pain, muscle or joint discomfort, pain in arms or legs

  • Nausea, vomiting, diarrhea, decreased appetite

  • Anemia, rash, symptoms of low blood pressure

  • Nasopharyngitis (stuffy nose)